Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab or Nimotuzumab with Chemotherapy in EGFR-amplified Advanced Gastric Cancer
NCT04136600Phase 2Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jul 2019
- Primary completion
- Aug 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of KL-140 and nimotuzumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Progression-Free Survival at 2 years and Objective Response Rate at 2 years. Status: unknown.
02
Drugs
KL-140nimotuzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04136600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136600.